Green Spectrophotometric Quantification of Alfuzosin HCl in BPH Tablets

Study Background and Research Question

Benign prostatic hyperplasia (BPH) is a prevalent condition among elderly men, often accompanied by lower urinary tract symptoms (LUTS) and erectile dysfunction. Combination therapies targeting both symptom domains are increasingly being developed, with fixed-dose tablets containing Alfuzosin HCl—a selective α1 adrenoceptor antagonist—and tadalafil, a phosphodiesterase 5 inhibitor, representing recent pharmaceutical advances. Accurate, efficient quantification of these actives in combination formulations is essential for both research and quality assurance in BPH studies. While established chromatographic and spectrofluorometric methods exist, a simple, cost-effective, and environmentally friendly spectrophotometric assay for simultaneous quantification had not been reported until the study by Alqahtani et al. (DOI: 10.1186/s13065-024-01201-7).

Key Innovation from the Reference Study

The primary innovation of Alqahtani et al. lies in the development and validation of two green spectrophotometric methods—absorbance subtraction and ratio difference—for concurrently quantifying Alfuzosin HCl and tadalafil in their binary mixture. These approaches circumvent the spectral overlap that previously limited the use of direct spectrophotometry for such combinations. Importantly, both methods are designed to be straightforward and do not require extensive sample preparation or complex instrumentation, marking a significant step toward sustainable analytical practices in pharmaceutical research and manufacturing [source_type: paper][source_link: https://doi.org/10.1186/s13065-024-01201-7].

Methods and Experimental Design Insights

The spectral overlap between Alfuzosin HCl and tadalafil complicates their simultaneous determination by conventional spectrophotometry. To address this, the researchers employed two mathematical manipulation techniques:

• Absorbance Subtraction Method: This approach uses the zero absorption spectra at an isoabsorptive point (272 nm), along with the known absorbance factor of Alfuzosin HCl, to mathematically resolve the absorbance contributions of each compound in the mixture. This enables accurate quantification without physical separation [source_type: paper][source_link: https://doi.org/10.1186/s13065-024-01201-7].
• Ratio Difference Method: Here, the absorbance spectra of each drug are divided by a reference spectrum of the other, generating ratio spectra. By measuring the difference in amplitude at carefully selected wavelengths (251 nm and 211 nm for Alfuzosin HCl; 292 nm and 222 nm for tadalafil), the method establishes a direct proportionality between amplitude difference and analyte concentration.

Both methods were rigorously validated according to International Council for Harmonisation (ICH) criteria, ensuring their reliability and reproducibility for pharmaceutical analysis.

Core Findings and Why They Matter

The study demonstrated that both absorbance subtraction and ratio difference methods provided accurate, precise, and selective quantification of Alfuzosin HCl and tadalafil in fixed-dose combination tablets. Key findings include:

• Linearity: The methods achieved linear regression for Alfuzosin HCl in the range of 1–15 μg/mL and for tadalafil in the range of 3–40 μg/mL [source_type: paper][source_link: https://doi.org/10.1186/s13065-024-01201-7].
• Accuracy and Precision: Both techniques met ICH guidelines for recovery and repeatability, with negligible matrix interference, making them suitable for routine QC and research applications.
• Green Chemistry Advantages: The approaches are cost-effective and minimize solvent consumption, aligning with sustainable laboratory practices.

For BPH research, the ability to reliably quantify Alfuzosin HCl—a functionally uro-selective α1 adrenoceptor antagonist—when combined with tadalafil supports investigation into synergistic mechanisms, such as enhanced smooth muscle relaxation and improved LUTS outcomes [source_type: paper][source_link: https://doi.org/10.1186/s13065-024-01201-7]. This expands the analytical toolkit for studies on the inhibition of intraurethral pressure, lower urinary tract smooth muscle relaxation, and the α1-adrenergic receptor signaling pathway.

Comparison with Existing Internal Articles

Several internal resources provide context for these advances. For example, the article "Unlocking Uroselectivity: Strategic Insights for Translational BPH Research" discusses the mechanistic underpinnings of Alfuzosin HCl as a functionally uro-selective α1-adrenoceptor antagonist and addresses the challenges in translating receptor pharmacology into clinical outcomes. The present study complements these insights by supplying validated spectroscopic methods that facilitate experimental reproducibility and robust quantification—critical for the translational workflow.

Additionally, the internal article "Alfuzosin Hydrochloride: Mechanistic Insights, Analytical Innovation, and BPH Research" highlights the need for reliable analytical methods in mechanistic and translational studies. The green spectrophotometric protocols developed by Alqahtani et al. directly address this need by providing accessible, validated tools for dual-analyte quantification in BPH research formulations.

Limitations and Transferability

While both methods have demonstrated robustness and selectivity for fixed-dose combination tablets, several limitations must be acknowledged:

• Matrix Specificity: The validation focused on pharmaceutical tablet matrices; applicability to other complex biological or experimental matrices may require additional validation steps [source_type: paper][source_link: https://doi.org/10.1186/s13065-024-01201-7].
• Instrumental Constraints: The methods rely on access to UV–Vis spectrophotometers with the necessary wavelength accuracy and resolution.
• Range Limitations: The quantification ranges (1–15 μg/mL for Alfuzosin HCl) are optimal for tablet formulations; adaptations may be needed for lower-concentration biological samples.

Despite these caveats, the methods are transferable to other laboratories with routine spectrophotometric capabilities, offering a pragmatic alternative to more resource-intensive chromatographic techniques.

Protocol Parameters

• assay | 1–15 μg/mL (ALF linearity range) | Pharmaceutical tablet quantification | Validated working range for Alfuzosin HCl in binary mixtures | paper [DOI]
• assay | 3–40 μg/mL (TAD linearity range) | Pharmaceutical tablet quantification | Validated working range for tadalafil in binary mixtures | paper [DOI]
• release medium | 0.1 N HCl | In vitro dissolution studies | Standard medium for Alfuzosin HCl release testing | product_spec [APExBIO]
• solubility | ≥47.8 mg/mL in water | Solution preparation for in vitro use | Facilitates preparation of ALF standards for spectrophotometric analysis | product_spec [APExBIO]
• drug loading | 10 mg per dosage unit | Tablet formulation studies | Common loading for Alfuzosin HCl in pharmaceutical forms | product_spec [APExBIO]

Research Support Resources

Researchers seeking to replicate or extend these spectrophotometric workflows may consider Alfuzosin Hydrochloride (SKU A5173) from APExBIO, which offers high solubility in common assay solvents and is suitable for in vitro and spectroscopic applications [source_type: product_spec][source_link: https://www.apexbt.com/alfuzosin-hcl.html]. For further background on assay optimization and mechanistic studies using Alfuzosin HCl as an α1 adrenoceptor antagonist, the resource "Alfuzosin Hydrochloride: Mechanistic Insights, Analytical Innovation, and BPH Research" provides additional guidance.